Epigenetic Alterations in AML
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Leukemia
- Sponsor
- Children's Oncology Group
- Enrollment
- 15
- Primary Endpoint
- Relationships between genetic and epigenetic landscapes in AML
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarker changes in samples from young patients with acute myeloid leukemia.
Detailed Description
OBJECTIVES: * Map key histone modifications and cytosine methylation in leukemia cell lines with defined oncogenic mutations. * Acquire genome-wide maps of key histone modifications and cytosine methylation for primary leukemia in samples from patients with acute myeloid leukemia (AML). * Investigate functional relationships between genetic and epigenetic landscapes in AML. OUTLINE: Archived samples are analyzed in vivo and in vitro (cell line) for histone modification and cytosine methylation. Genome-wide locations of 5 histone modifications are analyzed using chip-Seq, as well as DNA methylation analysis at nucleotide-resolution by high-throughput bisulfite sequencing. These epigenetic data are correlated with genomic data (sequence analysis, expression array, SNP array).
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Relationships between genetic and epigenetic landscapes in AML